Prostate biopsy: how it works, what the results show, risks, and modern approaches

Below, "prostate puncture" refers to a needle biopsy of the prostate gland, which involves taking small tissue cores for microscopic examination. In clinical practice, biopsy remains the method by which cancer is confirmed, rather than simply suspected based on a blood test, digital examination, orMRI data. [1] [2]

Just 10-15 years ago, many patients underwent a biopsy almost immediately after an elevated prostate-specific antigen level. Today, the approach has become more precise: first, age, family risk, digital examination, prostate-specific antigen density, previous results, and magnetic resonance imaging data are assessed. Only then is a decision made on whether a biopsy is necessary and which procedure would be optimal. [3] [4] [5]

The primary goal of a modern biopsy isn't simply to "find any cancer," but to detect a clinically significant tumor that truly requires treatment or particularly close monitoring. This is important because some tumors grow slowly and may never cause harm, while others require rapid and accurate diagnosis. [6] [7]

Therefore, biopsy itself is no longer considered a separate procedure, but rather as part of the diagnostic pathway. The 2026 European guidelines specifically updated the sections related to magnetic resonance imaging and biopsy strategy, reflecting the rapid change in practice in this direction. [8] [9]

For the patient, this means something simple but important: today, "puncture" has become more targeted. Doctors strive to take fewer unnecessary samples, miss dangerous tumors less often, and, where possible, reduce the risk of infection, bleeding, and unnecessary treatment. [10] [11] [12]

What does the method provide?	What it doesn't replace
Confirms or excludes the presence of tumor cells	Does not replace a prostate-specific antigen blood test
Allows you to determine the degree of tumor aggressiveness	Does not replace digital examination
Helps choose between observation, surgery, radiation therapy, or another option	Does not replace magnetic resonance imaging as a navigation method
Determines whether there are precancerous changes or questionable lesions	Does not provide a complete picture of the stage without additional methods
Serves as the basis for the final morphological diagnosis	It is not a treatment in itself.

Sources for the table: [13] [14] [15]

When a puncture is really necessary, and when the decision can be postponed

The most common reason for a biopsy is not a "bad test result" per se, but a combination of features that increase the likelihood of clinically significant cancer. This could include an elevated prostate-specific antigen level, a suspicious area on digital prostate examination, a previously atypical biopsy result, or a worrisome lesion on magnetic resonance imaging. [16] [17]

Current guidelines emphasize that magnetic resonance imaging (MRI) prior to a first or repeat biopsy often helps make more informed decisions. If the images reveal a suspicious lesion, the biopsy can be directed precisely to that lesion. A negative MRI does reduce the likelihood of a dangerous tumor, but it does not always allow the procedure to be avoided entirely. [18] [19] [20]

It is especially important to understand that a negative MRI does not mean absolute safety. European guidelines explicitly state that in cases of high clinical suspicion, such as high prostate-specific antigen density, a systemic biopsy may remain necessary even with negative images. [21]

On the other hand, there are situations where the doctor and patient may consciously take their time. The UK National Institute for Health and Clinical Excellence recommends discussing prostate-specific antigen levels, digital examination results, comorbidities, age, risk factors, and previous biopsy results together. In cases of low MRI results, it is sometimes acceptable to forgo a biopsy after a joint decision. [22] [23]

A negative biopsy does not automatically end the process. American guidelines emphasize that the decision to repeat a biopsy should not be based solely on the prostate-specific antigen threshold; a repeat risk assessment is necessary, and if a previous magnetic resonance imaging scan is not available, it should be performed before a repeat biopsy. [24] [25]

Clinical situation	What do people do more often today?
Elevated prostate-specific antigen, suspicious lesion on magnetic resonance imaging	Perform targeted biopsy, often in conjunction with systemic
Prostate-specific antigen is elevated, magnetic resonance imaging is negative, but the risk is high	A systemic biopsy is being considered.
The first biopsy is negative, the risk remains	They reassess the risk, perform magnetic resonance imaging, and decide on a repeat biopsy.
Low risk and low magnetic resonance imaging score	A biopsy may be declined after discussing the risks and benefits.
There are serious comorbidities and limited life expectancy.	The decision is individualized, sometimes invasive diagnostics are postponed

Sources for the table: [26] [27] [28] [29]

How to prepare for the procedure

Preparation begins not on the examination couch, but several days before the biopsy. The doctor will determine whether you have had urinary tract infections, urinary problems, episodes of urinary retention, diabetes, use of blood thinners, and tolerance to antibiotics or anesthesia. This is important because the access route and complication prevention measures are selected individually. [30] [31]

Before the procedure, a urine sample is often requested to rule out a current infection. If an infection is confirmed, the biopsy is usually postponed until after treatment, as puncturing infected tissue increases the risk of serious complications. [32]

The use of medications that affect blood clotting is always decided on an individual basis. In practice, temporary adjustments to warfarin, aspirin, ibuprofen, and certain supplements are often required, but there is no universal rule: the physician balances the risk of bleeding with the risk of thrombosis, especially in patients with atrial fibrillation, stents, or a history of thrombosis. [33] [34]

If a transrectal biopsy is planned, a cleansing enema and antibacterial prophylaxis may be recommended. For perineal biopsy, the approach is different: current European guidelines allow for the omission of antibiotics in patients without risk factors for infectious complications, with mandatory perineal skin preparation as for routine surgical procedures. [35] [36]

Many patients are concerned about pain. In reality, a significant portion of biopsies today are performed on an outpatient basis under local anesthesia, especially with perineal access and modern guidance devices. This does not make the procedure pleasant, but it makes it quite tolerable for most people. [37] [38]

What to discuss before a biopsy	Why is this important?
Urinary tract infection, fever, burning sensation when urinating	The procedure may be postponed until treatment
Taking medications that affect blood clotting	It is necessary to reduce the risk of bleeding without unnecessary risk of thrombosis.
Previous negative biopsy	May change the strategy and volume of tissue collection
Magnetic resonance imaging results	They determine whether the biopsy will be targeted
Diabetes mellitus, urinary retention, severe concomitant diseases	Affect the risk of complications and the choice of access
Drug allergies and anesthesia tolerance	Helps to safely select prevention and pain relief

Sources for the table: [39] [40] [41]

How is puncture performed today?

Historically, the most common route was the transrectal route, where the needle passes through the rectal wall. This method is still used today and is technologically familiar to many clinics, but its main drawback is obvious: the needle passes through an area with a high bacterial load, therefore increasing the risk of infection and sepsis. [42] [43]

A perineal biopsy is performed through the skin of the perineum, that is, through the area between the scrotum and anus. It is also performed under ultrasound guidance, but allows for better access to the anterior portions of the prostate gland while significantly reducing the risk of infection. This is why European guidelines now explicitly recommend performing a perineal biopsy. [44] [45]

European guidelines also provide specific figures: in a review of 162,577 patients, the sepsis rate was 0.1% after perineal biopsy and 0.9% after transrectal biopsy. In randomized trials and meta-analyses, infectious complications were also consistently lower with the perineal approach, which is especially important given the global rise in bacterial resistance to antibiotics. [46]

The next important shift is the transition from "blind" systemic biopsy to magnetic resonance imaging (MRI) guidance. If a suspicious lesion is visible on the images, the physician takes targeted cores from that lesion. This increases the likelihood of detecting clinically significant cancer while simultaneously reducing the detection of insignificant tumors, which previously often led to unnecessary treatment. [47] [48]

However, targeted biopsy does not always completely replace systemic biopsy. European data show that adding targeted biopsy to systemic biopsy in previously biopsied patients increases the detection of clinically significant cancer by approximately 20-30%, while omitting the systemic component may result in missing some important tumors. Therefore, in many patients, especially during initial diagnosis, physicians choose a combined approach. [49] [50]

A repeat biopsy is worth mentioning separately. American guidelines recommend first performing an MRI, if one hasn't already been performed. If a lesion is present, a targeted biopsy is performed and a systemic biopsy may be added. If there is no lesion, but suspicion remains, a systemic biopsy is still acceptable. [51]

Biopsy option	Strong point	Weakness	Where it is especially useful
Transrectal systemic	Technically familiar, accessible	Higher risk of infection	Where the perineal pathway has not yet been implemented
Perineal systemic	Lower risk of infection, better access to the anterior sections	May more often cause temporary urinary retention and blood in the urine	The modern preferred path
Targeted according to magnetic resonance imaging data	Better detection of clinically significant lesions	May miss some tumors without a systemic component	If the lesion is visible on the images
Systemic	Covers the entire gland according to the template	Less precision, more over-examination	With a negative magnetic resonance imaging and a persistent risk
Combined	Maximizes detection of significant cancer	More punctures and the risk of over-detection of slow-growing tumors	Often used in primary diagnostics and complex cases

Sources for the table: [52] [53] [54] [55]

What does the biopsy report show?

After the procedure, tissue samples are sent to a pathologist. They answer not only the question "is there cancer?" but also describe the cell type, the degree to which they differ from normal tissue, the number of affected columns, and the tumor volume in each column. This conclusion then determines the treatment plan. [56] [57]

If a tumor is detected, the response almost always includes a Gleason score and grade group. These are different forms of the same information about the tumor's biological aggressiveness. The higher the final score and grade group, the higher the likelihood of faster growth and the more carefully the physician discusses active treatment. [58]

In modern clinical language, grade groups are more convenient for patients than the Gleason score. Grade 1 typically corresponds to the least aggressive variants, and grade 5 to the most aggressive. But even this indicator is never considered in isolation: prostate-specific antigen levels, magnetic resonance imaging data, the number of positive columns, and clinical stage are also important. [59] [60]

Sometimes the answer is neither completely negative nor completely positive. The pathologist may describe high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation. This is not the same as confirmed cancer, but may require further investigation, re-assessment of risk, and sometimes a repeat biopsy using modern algorithms. [61] [62]

It is also important to remember the potential for tumor underestimation. Even a high-quality biopsy examines only part of the gland. Therefore, a combination of magnetic resonance imaging, targeted cores, and systemic sampling often improves classification accuracy compared to standard systemic biopsy alone. [63] [64] [65]

Pathologist's response element	What does it mean for the patient?
No cancer detected	At this point, there is no confirmation of the tumor, but further tactics depend on the overall risk
High-grade prostatic intraepithelial neoplasia	Precancerous change, requires clinical evaluation
Atypical small acinar proliferation	A suspicious but not final change
Gleason score 6	Usually corresponds to malignancy grade group 1
Gleason score 7, option 3 plus 4	Usually corresponds to group 2
Gleason score 7, option 4 plus 3	Usually corresponds to group 3
Gleason score 8	Usually corresponds to group 4
Gleason score 9 or 10	Usually corresponds to group 5

Sources for the table: [66] [67]

Complications, recovery, and warning signs

Most patients tolerate the biopsy without serious consequences, especially if it is performed through the perineum with modern preparation. However, it is an invasive procedure, so slight blood in the urine, stool, or semen, mild soreness, and temporary discomfort afterward are considered to be expected. [68] [69]

Blood in semen can persist longer than many expect, sometimes for several weeks. This symptom is what most often alarms patients, although in most cases it is not a sign of disaster and resolves on its own. It is much more important to pay attention not to the staining itself, but to increasing bleeding, clots, inability to urinate, or a worsening of general condition. [70] [71]

The main complication that is especially sought to be avoided is infection. For this reason, global practice is gradually shifting toward perineal biopsy. A 2024 randomized trial and European guidelines show that infectious complications after perineal access are less common, and in patients without risk factors, antibiotics may sometimes be omitted altogether. [72] [73]

Another complication is temporary urinary retention. This is much less common than mild bleeding, but requires prompt medical attention, as a temporary catheter may be needed. The risk is higher in patients with significant gland enlargement, underlying urinary problems, and after larger tissue collection procedures. [74] [75]

Following a biopsy, it is usually recommended to avoid strenuous physical activity for 24-48 hours, drink plenty of fluids, and closely monitor temperature, urination, and bleeding. Most people return to normal activity quickly, but the first 1-3 days are important for early detection of infection or urinary retention. [76] [77]

Fever, chills, severe weakness, increasing pain, inability to urinate, and severe or persistent bleeding are considered reasons for urgent medical attention. These signs are more important than the usual moderate blood impurities, as they may indicate infection, significant bleeding, or urinary tract obstruction. [78] [79] [80]

After a biopsy, this is usually acceptable.	After a biopsy, it is necessary to contact your doctor.
A little blood in the urine	Temperature, chills
Minor bleeding from the rectum after transrectal access	Inability to urinate
Blood in semen for several weeks	Heavy or increasing bleeding
Mild pain and pressure	Increasing pain
Moderate discomfort during the first day	Severe weakness, signs of infection

Sources for the table: [81] [82] [83] [84]

Where is the method heading today?

The most noticeable trend is the shift toward a "first magnetic resonance imaging (MRI), then targeted biopsy only for those who truly require it" approach. European and American guidelines have already integrated this principle into current algorithms, and the 2026 updates directly address indications for biopsy based on MRI data. [85] [86]

The second trend is a move away from the transrectal approach as a universal standard. The UK's National Institute for Health and Clinical Excellence has already recommended perineal biopsy under local anesthesia as an acceptable diagnostic technique, and European guidelines have made the perineal route preferred precisely because of its lower rate of infections and better antibiotic tolerance. [87] [88]

The third trend is the more intelligent use of negative MRI. Studies show that in some patients, it allows for safe biopsy avoidance and a reduction in the number of clinically insignificant cancer diagnoses, but not in all. In high-risk settings, a negative MRI cannot be relied upon completely. [89] [90]

The fourth trend is personalized care after a negative biopsy. Instead of the old approach of "if prostate-specific antigen levels rise again, repeat the injection," American guidelines recommend reassessing overall risk, using calculators, selectively using biomarkers, and repeat magnetic resonance imaging. This reduces the number of unnecessary repeat injections. [91] [92]

Finally, new tools are gradually being developed: shorter magnetic resonance imaging protocols, microultrasound, artificial intelligence algorithms for image interpretation, and combined risk models. However, for now, needle biopsy remains the final morphological point, without which it is impossible to reliably confirm the diagnosis and determine the degree of malignancy. [93] [94] [95]

What's changing?	Why is this important for the patient?
Magnetic resonance imaging is increasingly being used before biopsy.	Fewer unnecessary procedures
The perineal route displaces the transrectal route	Lower risk of infection and better antibiotic control
Decisions are increasingly made based solely on prostate-specific antigen levels.	Fewer unnecessary repeat biopsies
Combined strategies are applied selectively, not automatically to everyone.	Balance between precision and invasiveness
Risk calculators, micro-ultrasound, and artificial intelligence are developing	More personalized diagnostics

Sources for the table: [96] [97] [98] [99]

FAQ

Is it very painful?

Most modern biopsies are performed under local anesthesia, so the procedure is generally well-tolerated. Some discomfort is possible, especially during tissue sampling, but severe, unbearable pain is not typical for a standard outpatient biopsy. [100] [101]

Is it possible to do without a puncture if the magnetic resonance imaging is good?

Sometimes yes, but not always. In low-risk cases with a low MRI score, a biopsy may be considered after discussion with a physician. However, in high-risk cases, a negative MRI does not preclude the need for a systemic biopsy. [102] [103]

Which method is considered more modern and safe today?

Perineal biopsy is considered preferable due to the risk of infectious complications. This is why European guidelines prioritize it, and the UK's National Institute for Health and Clinical Excellence supports its use under local anesthesia. [104] [105]

If the first biopsy is negative, does that mean there is definitely no cancer?

No. A negative result reduces the risk, but does not eliminate it. After a negative biopsy, a repeat decision is made based on a combination of factors, not just the prostate-specific antigen level alone. [106] [107]

How long does blood in semen last after the procedure?

This can last for several weeks and is often the most long-term, but still expected, consequence. It is more important to pay attention to fever, inability to urinate, and increasing bleeding. [108] [109]

What is more important: targeted or systemic biopsy?

There is no universal answer. Targeted biopsy is better at identifying significant lesions on magnetic resonance imaging, but in some patients, the addition of systemic columns improves overall diagnostic accuracy. Therefore, a combined approach is often used in practice. [110] [111]

Key points from experts

Philip Cornford, Professor, Consultant Urological Surgeon, Chair of the European Association of Urology's Prostate Cancer Guidelines Committee.
From a practical perspective, his key message for patients is that biopsy should be part of a risk-based approach, not a reflex response to a single elevated test result. This explains the move by the European guidelines to update the sections on magnetic resonance imaging, risk calculators, and biopsy strategy. [112] [113] [114]

Aivo Schots, Associate Professor and Head of the Abdominal Imaging Research Unit at Erasmus Medical Center,
has consistently shown that magnetic resonance imaging can improve the selective detection of clinically significant cancer while simultaneously reducing the number of unnecessary biopsies. However, this approach works best not on its own, but in conjunction with appropriate risk stratification and patient selection. [115] [116]

Jim Hu, professor of urology and urological oncologist at Weill Cornell Medical College,
has a simple practical message in the 2024 randomized trial he is named after: perineal biopsy helps reduce infectious complications and makes diagnosis safer without sacrificing clinical value. For patients, this is one of the most compelling arguments why modern clinics are increasingly moving away from the transrectal route. [117] [118]

Mohamad Allaf, professor of urology and oncology, director of the Brady Urological Institute and urologist-in-chief at Johns Hopkins Hospital,
said: "His clinical position in the current literature aligns well with the general logic of the latest guidelines: diagnostic accuracy increases when biopsy is chosen not out of habit, but with a goal—to reduce the risk of infection, not to miss significant tumors, and to minimize the overdetection of slow-growing cancers." [119] [120] [121]

Conclusion

Today, prostate puncture is no longer just "12 random punctures," but a highly personalized diagnostic procedure. The best modern results are achieved by a procedure that first assesses risk and magnetic resonance imaging data, then selects the optimal approach, and, after a biopsy, interprets not only the presence of a tumor but also its biological aggressiveness. [122] [123]

For most patients, the key practical lessons are: avoid biopsy without a clear purpose, discuss the perineal route with your doctor, discuss blood-thinning medications in advance, and closely monitor temperature, urination, and bleeding after the procedure. This approach makes diagnosis more accurate, safer, and more useful for deciding on further treatment. [124] [125] [126]